Search
Showing results for "clinical trials"
An NHMRC grant exploring epigenetic factors that affect wheezing and asthma development.
The DiabHQ Patient Portal App is coming soon!
The year 2013 saw the progress in our research from purely lab-based studies towards taking a step closer to translational research.
Our team of world-class researchers and exceptional clinicians work in collaboration to provide children access to the very best evidence-based therapies and programs.
Communication impairments are a leading concern for parent caregivers of individuals with rare neurodevelopmental disorders. Clinical trials of disease modifying therapies require valid and responsive outcome measures that are relevant to individuals with RNDDs. Identifying and evaluating current psychometric properties for communication measures is a critical step towards the selection and use of appropriate instruments.
Engaging the community in COVID-19 rapid research
Combination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs).
The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.
Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
To assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media